

1 **TFAZZIN REGULATES NEUTROPHIL MATURATION AND INFLAMMATORY** 2 **RESPONSE**

3 Przemysław Zakrzewski^{1,5}, Christopher M. Rice^{1,5}, Kathryn Fleming¹, Drinalda Cela¹, Sarah
4 J. Groves¹, Fernando Ponce¹, Willem Gibbs¹, Kiran Roberts², Tobias Pike¹, Douglas
5 Strathdee³, Eve Anderson³, Angela H. Nobbs⁴, Ashley Toyne², Colin Steward¹ and Borko
6 Amulic^{1,6}

- 7 1. School of Cellular and Molecular Medicine, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
8 2. School of Biochemistry, Biomedical Sciences Building, University of Bristol, Bristol, BS8 1TD, UK.
9 3. Cancer Research UK Scotland Institute, Glasgow, G61 1BD, UK
10 4. Bristol Dental School Research Laboratories, Dorothy Hodgkin Building, University of Bristol, Bristol, BS1 3NY, UK
11 5. Contributed equally
12 6. Corresponding author

13 **Correspondence to:** borko.amulic@bristol.ac.uk

14 **ABSTRACT**

15 Barth syndrome (BTBS) is a rare genetic disease caused by mutations in
16 the *TFAZZIN* gene. It is characterized by neutropenia, cardiomyopathy and skeletal
17 myopathy. Neutropenia in BTBS is associated with life-threatening infections, yet there
18 is little understanding of the molecular and physiological causes of this phenomenon.

19 We combined bone marrow analysis, CRISPR/Cas9 genome editing in hematopoietic
20 stem cells and functional characterization of circulating BTBS patient neutrophils to
21 investigate the role of *TFAZZIN* in neutrophils and their progenitors. We demonstrate
22 a partial cell intrinsic differentiation defect, along with a dysregulated neutrophil
23 inflammatory response in BTBS, including elevated formation of neutrophil
24 extracellular traps (NETs) in response to calcium flux. Developmental and functional
25 alterations in BTBS neutrophils are underpinned by perturbations in the unfolded
26 protein response (UPR) signaling pathway, suggesting potential therapeutic avenues

27 **NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
for targeting BTBS neutropenia.

28 **INTRODUCTION**

29 Barth syndrome (BTHS) is a rare X-linked genetic disease characterized principally by
30 dilated cardiomyopathy, skeletal myopathy, and neutropenia [1-3]. Mutations in the
31 *TFAZZIN* gene, encoding a mitochondrial lipid transacylase, are the primary cause
32 of BTHS [4]. Tafazzin is essential for remodeling and maturation of cardiolipin (CL), a
33 major phospholipid of the mitochondrial inner membrane, which has a crucial role in
34 maintaining mitochondrial structure and function [2, 5]. *TFAZZIN* mutations lead to
35 an accumulation of an intermediate CL species, monolysocardiolipin (MLCL),
36 impairing mitochondrial metabolism and contributing to defects in cardiomyocytes and
37 skeletal muscle, which have abundant mitochondria and are dependent on efficient
38 oxidative respiration [6]. Apart from regulating ATP generation, CL has been
39 implicated in signaling [7, 8], control of apoptosis [8, 9], generation of mitochondrial
40 reactive oxygen species (ROS) [9], and regulation of calcium homeostasis [10].
41 Furthermore, mitochondria are important regulators of inflammation, and it has been
42 suggested that dysregulated inflammatory response is a component of BTHS [11],
43 although there is a major lack of knowledge on the innate immune response in
44 patients. Neutropenia and neutrophil-mediated inflammation are possible targets for
45 therapeutic interventions, to improve patient wellbeing and survival.

46 Neutropenia is detected in approximately 84% of BTHS patients and shows various
47 patterns [1, 3, 12], including intermittent and unpredictable, chronic or severe, or truly
48 cyclical [12]. Neutrophils kill microbes by phagocytosis, generation of ROS, release of
49 antimicrobial proteins stored in secretory granules, and formation of neutrophil
50 extracellular traps (NETs), which consist of externalized chromatin decorated with
51 antimicrobial proteins [13]. NETs can trap microbes and prevent their dissemination
52 but are also sensed by other innate and adaptive immune cells, leading to

53 proinflammatory cytokine production and propagation of inflammation [14].
54 Importantly, neutropenia in BTHS is associated with various bacterial infections, which
55 are the second leading cause of death in these patients [1].

56 Despite the prominence of neutropenia in BTHS patients, there is little understanding
57 of the molecular and physiological causes of this phenomenon [12]. Neutropenia can
58 result from defects in neutrophil production in the bone marrow, elevated apoptosis or
59 from enhanced removal of activated neutrophils from the circulatory system [15-17].

60 Limited investigation of bone marrow in BTHS led to conflicting reports: hypocellularity
61 and reduced myeloid maturation were detected in some BTHS patients without a clear
62 block in neutrophil maturation [12, 18], and short-term colony assays using
63 hematopoietic stem cells (HSCs) purified from patient blood failed to detect any
64 defects in neutrophil differentiation *in vitro* [18, 19]. One study described elevated
65 annexin V binding in circulating BTHS neutrophils, without increased apoptosis or
66 phagocytic clearance by macrophages [19]. On the other hand, studies using shRNA-
67 mediated *TAFAZZIN* knockdown in myeloid cell lines demonstrated increased
68 caspase-3 activation, release of cytochrome c from mitochondria, and accelerated
69 apoptosis in response to tafazzin deficiency [20]. There is therefore no consensus on
70 the mechanism of neutropenia in BTHS patients.

71 In mice, tafazzin deficiency causes embryonic lethality in C57BL/6 mice [21, 22],
72 although other genetic backgrounds are viable. Immortalization of murine embryonic
73 *Tafazzin*-KO myeloid progenitors demonstrated normal differentiation into mature
74 neutrophils, normal mitochondrial electron transport chain assembly, and equivalent
75 functional responses to wild-type (WT) cells [23]. The study did, however, detect
76 slightly enhanced susceptibility to apoptosis upon Bcl-2 inhibition and subtle

77 perturbations in expression of unfolded protein response (UPR) genes, raising the
78 possibility that ER-mediated stress may affect viability of BTHS cells [23].

79 To address the gap in understanding of BTHS neutropenia, we combined patient bone
80 marrow analysis with our recently developed *ex vivo* neutrophil differentiation system
81 [24] to investigate the role of *TAFAZZIN* in neutrophil development from HSCs. We
82 also performed a comprehensive analysis of neutrophil phenotype and function in
83 BTHS patients, including proteomic analysis. Our work reveals a partial block in
84 neutrophil differentiation and maturation in BTHS, accompanied by elevated
85 intercellular calcium, hyperdegranulation, and evidence of enhanced NET formation.
86 We detect alterations in the UPR pathway and propose that this may be a potential
87 cause of the observed defects in BTHS neutrophils.

88

89 **RESULTS**

90 **Partial block in bone marrow neutrophil maturation in BTHS**

91 We examined neutrophil morphology in bone marrow aspirates of 5 BTHS patients (4-
92 24 years old; all treated with G-CSF). The samples had similar features and were
93 characterized by normocellularity, normal megakaryopoiesis and erythropoiesis, and
94 unaffected eosinophil lineage (Fig. 1A, S1A). As expected with G-CSF treatment, all
95 samples exhibited marked 'left shift' i.e. an elevated number of granulocyte precursors
96 – promyelocytes and myelocytes. However, there was a notable decrease in the
97 number of metamyelocytes and mature neutrophils compared to values observed in
98 healthy individuals; this was reflected in substantially reduced myeloid to erythroid
99 ratio (Fig. 1B). These findings demonstrate a defect in neutrophil maturation in BTHS,
100 as previously suggested [12, 18].

101 **Impaired *ex vivo* terminal differentiation and maturation of BTHS neutrophils**

102 To date, there have been no studies of maturation of tafazzin deficient neutrophils
103 using primary human progenitors. Our laboratory recently optimized a protocol to
104 differentiate human neutrophils from CD34⁺ HSCs isolated from a small amount of
105 peripheral blood (Fig. 1C, adapted from [24]). This protocol yields approximately 50%
106 mature neutrophils, defined as CD66b⁺CD15⁺ cells. We used this system to compare
107 neutrophil differentiation from CD34⁺ progenitors of healthy control (HC) and BTHS
108 patients, recruited from the NHS National Barth Syndrome Service at Bristol Royal
109 Hospital for Children. We did not observe any difference in total cell number over 17
110 days of cell differentiation (Fig. 1D) or in proliferation ratio of BTHS and HC cells (fold
111 change from day 3: HC = 90±37 vs. BTHS = 82±88); (Fig 1E). Moreover, there was
112 no increase in apoptosis or necrosis in a subset of BTHS cultured neutrophils (Fig.

113 **S1B**) or any evident morphological changes (**Fig. S1C**). However, flow cytometry (**Fig.**
114 **S1D**) uncovered an average 13.4% drop in the number of differentiated CD66b⁺CD15⁺
115 neutrophils (HC = 48.08±10.30% vs. BTHS = 34.69±9.68%; p = 0.0145); (**Fig. 1F**) and
116 a 31% decrease in relative expression of the maturity marker CD11b in BTHS samples
117 (HC = 1.00±0.25 vs. BTHS = 0.69±0.32; p = 0.0425); (**Fig. 1G**). Importantly, this
118 reduction was also reflected by an average 12.7% drop in the number of mature
119 CD66b⁺CD15⁺CD11b^{hi} neutrophils at the end of differentiation (HC = 37.08±5.80% vs.
120 BTHS = 24.40±7.26%; p = 0.0013) (**Fig. S1E**).

121 To confirm a cell-intrinsic role for tafazzin in control of neutrophil differentiation, we
122 performed shRNA knockdown experiments. First, to choose an optimal shRNA
123 construct, we used the myeloid cell line PLB-985 to screen 3 vectors encoding
124 *TAFAZZIN*-targeting shRNA. The most consistent results were obtained with shRNA
125 3, where we observed reductions in both expression of tafazzin and expression of
126 CD11b in differentiated cells (**Fig. S1F**). Next, we isolated CD34⁺ HSC from healthy
127 donors and treated them with control non-targeting or *TAFAZZIN*-targeting shRNA, on
128 day 3 of differentiation (corresponding to non-committed progenitors), which led to an
129 approximately 45% reduction in tafazzin expression (**Fig. S1G**). Similarly to BTHS
130 patient cultured neutrophils, *TAFAZZIN* shRNA progenitors differentiated less
131 efficiently than controls, as evidenced by a 28% reduction in CD11b expression at the
132 end of differentiation (**Fig. 1H**).

133 Finally, to test the effect of complete tafazzin deficiency, we used CRISPR/Cas9 to
134 target exon 3 in CD34⁺ HSCs (day 3/non-committed progenitors, n = 3), with a
135 scrambled gRNA serving as control. Western analysis confirmed complete tafazzin
136 knockout at day 17 of differentiation (**Fig. 1I**). Importantly, complete tafazzin deficiency
137 resulted in an approximately 50% reduction in cell proliferation, compared to

138 scrambled control, when comparing fold expansion between days 3 and 17 (scrambled
139 gRNA = 33 ± 15 vs. *TAFAZZIN* gRNA = 17 ± 9 , $p = 0.1394$) (Fig. 1J, S1H). Moreover,
140 similarly to shRNA-treated neutrophils, tafazzin knockout cells exhibited a ~15%
141 decrease in the expression of differentiation marker CD11b (Fig. 1K). In summary,
142 experiments using HSC-derived neutrophils demonstrate that tafazzin has a cell
143 autonomous role in regulating neutrophil differentiation and maturation from early
144 progenitors and confirm a partial block in granulopoiesis in BTHS patients.

145 **Immature status of circulating BTHS neutrophils**

146 We next examined circulating neutrophils in BTHS patients ($n = 15$, 4/15 not receiving
147 G-CSF therapy) and healthy controls ($n = 15$, all untreated). Flow cytometric
148 immunophenotyping of neutrophil surface markers in whole blood, using previously
149 described gating strategies [25], revealed significantly reduced levels of the maturity
150 marker CD10 (HC = 4036 ± 2343 vs. BTHS = 2168 ± 1969 ; $p = 0.0253$) and a trend
151 towards reduced expression of CD16 (FcYRIIIB) (HC = 20222 ± 10030 vs. BTHS =
152 14037 ± 9303 ; $p = 0.0908$); (Fig. 2A). We did not observe any differences in CD101 and
153 CD62L between HC and BTHS patients (Fig. S2B). Both CD10 and CD16 expression
154 were normal in G-CSF untreated BTHS patients ($n=4$, 'non-neutropenic patients');
155 (Fig. S2A). It must be stressed that these patients do not suffer from documented
156 neutropenia, suggesting that their hematopoietic compartment is not affected. G-CSF
157 mobilizes immature neutrophils from the bone marrow, resulting in accumulation of
158 circulating neutrophils with reduced CD10 and CD16 [26], making it difficult to
159 conclude whether the observed immaturity is due to G-CSF treatment or an intrinsic
160 feature of BTHS neutrophils.

161

162 **BTHS neutrophils exhibit elevated degranulation and competent bacterial killing**

163 We next used flow cytometry to examine neutrophil surface markers associated with
164 activation. Interestingly, the secondary granule marker CD66b expression was
165 significantly elevated on patient neutrophils (HC = 2385 ± 401 vs. BTHS = 4125 ± 1156 ;
166 $p < 0.0001$), suggesting increased *in vivo* exocytosis compared to HC (Fig. 2B). This
167 finding was independent of G-CSF therapy (Fig. S2C). To examine degranulation in
168 more detail, including exocytosis of primary granules, we isolated neutrophils using
169 negative selection and quantified exposure of the primary granule marker CD63, with
170 or without stimulation with the bacterial peptide *N*-formylmethionine-leucyl-
171 phenylalanine (fMLP). There was no significant difference in CD63 exposure in naïve
172 neutrophils. Upon fMLP stimulation, however, BTHS neutrophils (n=31) demonstrated
173 more than 1.7-fold increase in activation compared to HC (n=29); (HC = 1213 ± 700 vs.
174 BTHS = 2115 ± 1927 ; $p = 0.0032$); (Fig. 2C). To test if elevated degranulation occurs in
175 response to live bacteria, we stimulated purified neutrophils with *Streptococcus*
176 *pyogenes* and quantified exposure of CD66b over 40 minutes of co-incubation (Fig.
177 2D). We found elevated surface levels of the secondary granule marker in naïve BTHS
178 neutrophils, confirming our *in vivo* findings, as well as an approximately 2-fold increase
179 upon bacterial stimulation compared to HC. Finally, we quantified plasma abundance
180 of MPO, a primary granule protein, and found elevated circulating MPO levels in BTHS
181 patients compared to healthy control plasma samples (Fig. 2E). In summary,
182 neutrophils from BTHS patients are more prone to degranulation of primary and
183 secondary granules.

184 A previous report demonstrated elevated rates of phosphatidyl serine (PS)
185 externalization in BTHS neutrophils, although these levels were lower than those
186 typically associated with neutrophil apoptosis [19]. We stained a portion of our

187 neutrophils with annexin V to quantify PS surface exposure. As previously reported,
188 we observed increased PS exposure in naïve neutrophils (HC = $3.80 \pm 1.48\%$ vs. BTHS
189 = $6.31 \pm 2.02\%$; $p = 0.0344$); (Fig. 2F). To test whether elevated PS exposure in BTHS
190 neutrophils could result from increased degranulation, we demonstrated that fMLP
191 stimulation increases annexin V positivity approximately 3-fold both for HC and BTHS
192 neutrophils compared to unstimulated cells (HC = $17.86 \pm 12.88\%$ vs. BTHS =
193 $14.36 \pm 5.19\%$; not significant); (Fig. 2G).

194 Secondary granules contain multiple cytoadhesive molecules and augmented
195 degranulation might result in excessive endothelial interactions, leading to
196 sequestration of neutrophils in vascular beds. We therefore analyzed spleen and liver
197 histological sections from WT and *Tafazzin*-KO mice (Fig. S2D). We did not observe
198 any difference in the number of neutrophils in the vasculature and parenchyma of
199 these tissues, indicating normal levels of margination in mice under steady state
200 conditions. Interestingly, in contrast to what is observed in BTHS patients, *Tafazzin*-
201 KO mice, on FVB (sensitive to the Friend leukemia virus) genetic background, had
202 equivalent neutrophil counts to those of WT mice, suggesting no defects in
203 hematopoiesis (Fig. S2E).

204 Next, we investigated whether neutrophils from BTHS patients show other functional
205 alterations. Using a luminol based assay, we quantified ROS production in response
206 to phorbol 12-myristate 13-acetate (PMA) and concanavalin A (con A) and found no
207 significant differences compared to HC (Fig. 2H). Moreover, we found no difference in
208 NETs formation with the strong soluble inducer PMA (Fig. 2I). Moreover, BTHS
209 neutrophils phagocytosed pHrodo™ *Streptococcus pyogenes* at similar rates to HC
210 neutrophils (Fig. S2F). Finally, neutrophils from BTHS patients ($n=4$) and HC ($n=4$)
211 demonstrated equivalent killing rates of opsonized *S. pyogenes* bacteria (Fig. 2J). In

212 summary, BTHS neutrophils display enhanced secondary and primary degranulation,
213 normal PMA-induced NETosis and maintain effective killing of a Gram-positive
214 pathogen.

215 **Mitochondrial function is not affected in BTHS patient neutrophils**

216 Mitochondria in BTHS patient neutrophils have not previously been studied. We found
217 increased mitochondrial abundance in patients relative to control, quantified with
218 MitoTracker dye (HC = 1.00 ± 0.22 vs. BTHS = 1.66 ± 0.52 ; $p = 0.001$); (Fig. 3A).
219 Interestingly, BTHS patient neutrophils had reduced mitochondrial membrane
220 potential, as evidenced by reduction of tetramethylrhodamine ethyl ester (TMRE)
221 compared to HC neutrophils (HC = $31 \pm 19\%$ TMRE low cells vs. BTHS = $47 \pm 25\%$
222 TMRE low cells; $p = 0.0349$); (Fig. 3B), suggesting that the increased abundance may
223 be a compensatory mechanism for impaired activity. To test this hypothesis, we used
224 Seahorse metabolic flux analysis to test respiratory chain activity in isolated BTHS
225 primary neutrophils ($n = 8$, 4/8 treated with G-CSF) and HC. We found no significant
226 differences in mitochondrial ATP production, basal respiration, maximal respiration, or
227 spare respiratory capacity (Fig. 3C), arguing against gross functional impairment.

228 Finally, as several studies reported elevated mitochondrial ROS (mtROS) in BTHS
229 cardiomyocytes [2, 27], we quantified mtROS in BTHS neutrophils using a MitoSOX
230 flow cytometry assay. The percentage of MitoSOX-positive cells was elevated in BTHS
231 samples, both in homeostatic conditions (HC = 19.20 ± 15.72 vs. BTHS = 31.85 ± 16.66 ;
232 $p = 0.058$); (Fig. 3D) and after stimulation with fMLP (HC = $11.27 \pm 5.35\%$ vs. BTHS =
233 $30.79 \pm 17.46\%$; $p = 0.0084$); (Fig. 3E), although this difference was not observed when
234 plotting total MitoSOX MFI (Fig. S3A-B). Moreover, we did not detect any mtROS
235 differences in BTHS HSC-derived neutrophils in a limited number of samples (Fig.

236 **S3C-D**). In conclusion, mitochondria in GCSF-treated BTHS patients are
237 characterized by elevated abundance, reduced membrane potential and elevated
238 mtROS. However, we failed to detect significant impairment of overall mitochondrial
239 functionality.

240 **Increased calcium-induced NETosis in BTHS neutrophils**

241 Excessive mtROS can affect calcium homeostasis, which in turn can regulate
242 neutrophil activation [28]. As we observed increased mtROS in BTHS neutrophils, we
243 decided to quantify intracellular calcium level in these neutrophils using X-Rhod-1, a
244 cell permeant dye that exhibits increased fluorescence after binding Ca^{2+} . We found a
245 >2-fold increase in intracellular calcium level of circulating BTHS cells, compared to
246 HC neutrophils (HC = 1.00 ± 0.08 vs. BTHS = 2.33 ± 1.26 ; $p = 0.0025$); (**Fig. 4A**). To
247 determine whether this change is caused by G-CSF therapy or a cell-intrinsic effect of
248 tafazzin deficiency, we analyzed calcium levels in HSC-derived neutrophils and
249 observed an almost 3-fold increase in X-Rhod-1 signal in BTHS stem cell-derived
250 neutrophils, compared to HC (HC = 2570 ± 671 vs. BTHS = 5662 ± 1160 ; $p = 0.0162$);
251 (**Fig. 4B**). Calcium is an essential activator of neutrophil inflammatory responses [29],
252 prompting us to ask whether tafazzin deficient neutrophils have altered functional
253 responses. To test this, we utilized the calcium ionophore A23187, which induces
254 calcium influx across the plasma membrane and strongly activates neutrophils [30].
255 As expected, A23187 induced strong degranulation of primary granules, but we did
256 not observe any significant differences in CD63 surface exposure between control and
257 tafazzin CRISPR/Cas9 knockout HSC-derived neutrophils (**Fig. 4C**).

258 We next investigated NET formation in tafazzin knockout HSC-derived neutrophils in
259 response to calcium-independent (PMA) and calcium-dependent stimuli (A23187),

260 using a live cell imaging assay. There was no difference in chromatin release in
261 response to PMA (Fig. 4D). On the other hand, A23187-induced NETosis was
262 significantly increased in tafazzin knockout cells compared to control cells (Fig. 4E).
263 In conclusion, both circulating and stem cell derived BTHS neutrophils exhibit elevated
264 intracellular calcium concentration, which promotes higher rates of NET formation in
265 response to calcium ionophore.

266 **Elevated UPR signaling in BTHS patients**

267 To better understand developmental changes in BTHS patient neutrophils, we
268 performed tandem mass tag (TMT) proteomic analysis of circulating neutrophils from
269 patients (n = 4 G-CSF-treated and n = 1 untreated, non-neutropenic patient), as well
270 as healthy controls (n = 5). We detected a total of 4056 proteins (Fig. S5A), including
271 306 proteins with significantly altered expression ($p < 0.05$), 91 of which had >2-fold
272 difference. Ingenuity Pathway Analysis (IPA) revealed multiple significantly up- and
273 down-regulated pathways in BTHS neutrophils (Fig. 5A). Notably, the most strongly
274 enriched pathway in BTHS was oxidative phosphorylation (Fig. S5B), closely followed
275 by fatty acid oxidation (Fig. S5C), consistent with elevated mitochondrial load, as
276 detected with MitoTracker (Fig. 3C). Intriguingly, the second most enriched pathway
277 in BTHS neutrophils was the unfolded protein response (UPR), which was previously
278 implicated in neutrophil dysregulation in *Tafazzin*-KO mice [23]. Specifically, we
279 observed an upregulation of eight UPR proteins (Fig. 5B) and four proteins associated
280 with mitochondrial UPR (mt-UPR, Fig. 5C). These changes appeared to be G-CSF-
281 and neutropenia-dependent, as the only untreated, non-neutropenic patient in our
282 study consistently exhibited less pronounced alteration (sample *BTHS5*). Of note,

283 changes in the expression of mt-UPR proteins were more uniform among patients (Fig.
284 S5D).

285 To confirm these changes, we quantified UPR protein abundance by Western blot (Fig.
286 5D). To avoid confounding by G-CSF treatment, we used HSC-derived neutrophils
287 from BTHS patients and HC, which are exposed to equivalent amounts of G-CSF over
288 the 10 days of the differentiation protocol. Despite limited sample size, immunoblotting
289 confirmed overexpression of IRE1 α , BiP, HSP60, and enhanced phosphorylation of
290 eIF2 α (Fig. 5D, S5E).

291 UPR signaling is controlled by three upstream master regulators: ATF6, IRE1 α and
292 PERK. We tested pharmacological inhibitors targeting all 3 of these pathways in
293 differentiation of neutrophils from HSC and found that inhibition of UPR regulator
294 PERK with GSK2606414 leads to a partial block in neutrophil differentiation, as
295 evidenced by the reduced number of CD66b⁺CD15⁺ (DMSO = 51.12 \pm 15.79% vs.
296 PERKi = 39.02 \pm 18.92%; p = 0.043) and CD11b^{hi} (DMSO = 39.43 \pm 14.19% vs. PERKi
297 = 24.58 \pm 14.56%; p = 0.043) neutrophils (Fig. 5E), reduced CD11b surface expression
298 (DMSO = 1.00 \pm 0.44 vs. PERKi = 0.77 \pm 0.38, p = 0.254); (Fig. S5F), and diminished
299 proliferation by the end of the differentiation process (DMSO = 27 \pm 16 vs. PERKi =
300 9 \pm 8; p = 0.0064); (Fig. S5G). ATF6 inhibitor (Ceapin A7) and IRE1 α inhibitor (4 μ 8C)
301 did not affect development at the concentration tested (data not shown). To further
302 investigate the role of the PERK pathway in neutrophil differentiation, we used the
303 PERK activator CCT020312 to increase the activity of this signaling pathway. Similarly
304 to PERK inhibition, PERK activation exhibited a trend towards partial reduction of
305 neutrophil differentiation, as evidenced by reduction in numbers of CD66b⁺CD15⁺ cells
306 (DMSO = 61.73 \pm 9.39% vs. PERKa = 53.30 \pm 5.54%; p = 0.185) and CD11b^{hi} cells

307 (DMSO = $54.00 \pm 10.67\%$ vs. PERKa = $43.00 \pm 7.95\%$; $p = 0.153$); (Fig. 5F), and
308 reduced CD11b surface expression (DMSO = 1.00 ± 0.18 vs. PERKa = 0.78 ± 0.08 , $p =$
309 0.067); (Fig. 5H) although neither were statistically significant. We also observed a
310 similar trend towards diminished proliferation by the end of the differentiation process
311 (DMSO = 41 ± 11 vs. PERKa = 32 ± 12 ; $p = 0.301$); (Fig. 5I), although again these
312 differences were not significant. Taken together, these results implicate dysregulation
313 of unfolded protein response in impairment of neutrophil development in BTHS.

314

315 **DISCUSSION**

316 Despite the prominence of neutropenia in BTHS patients, our understanding of the
317 molecular and physiological causes of this phenomenon has been limited. Our study
318 reveals that tafazzin has a cell-intrinsic role in regulating neutrophil differentiation and
319 confirms a partial block in granulopoiesis in BTHS patients. We also show that tafazzin
320 deficient neutrophils exhibit enhanced degranulation and elevated rate of NETosis.
321 Finally, we confirm alterations in UPR signaling in BTHS neutrophils, which might be
322 a contributing factor to the observed developmental and functional changes.

323 We observed a decrease in the number of mature neutrophils in BTHS bone marrow
324 samples. This is consistent with the original bone marrow examination by Barth [18]
325 (n=2) and subsequent work [12] that demonstrated hypocellularity in some, but not all,
326 BTHS patients. It remains unclear whether reduction in bone marrow neutrophils exists
327 in a subset of patients and whether this is defined by the nature of the tafazzin mutation
328 or by extrinsic factors. The maturation deficiency largely manifests in later stages of
329 neutrophil development, affecting metamyelocytes and band neutrophils. How this
330 leads to neutropenia, rather than simply a decrease in maturity of circulating
331 neutrophils, remains unexplained, and implies the involvement of additional extrinsic
332 factors.

333 We did not observe any evident hallmarks of early apoptosis in BTHS cultured
334 neutrophils, which is reflected in largely unaltered proliferation rates. We showed that
335 primary BTHS neutrophils exhibited a modest increase in annexin V binding, which is
336 also induced by fMLP stimulation. Consistent with the conclusion of Kuijpers et al. [19]
337 that increased binding of annexin V does not correlate with apoptosis, we propose that
338 elevated PS in BTHS neutrophils results from increased neutrophil degranulation,

339 which is known to alter surface lipid composition and transiently expose PS [31, 32].
340 We conclude that neutropenia in BTHS patients is most likely not caused by
341 accelerated apoptosis.

342 Intriguingly, we also observed increased functional responses in tafazzin deficient
343 neutrophils. Both spontaneous and bacterial-induced degranulation were elevated in
344 patient neutrophils, although this was not observed when cells were cultured from
345 tafazzin knockout stem cells. This discrepancy may be due to the fact that knockout
346 neutrophils display a more severe developmental delay than patient cells and the
347 propensity to hyperdegranulate is masked by developmental delays in synthesis of
348 granule components in KO neutrophils. Alternatively, unknown circulating factors in
349 patient plasma, such as inflammatory cytokines, may be priming circulating neutrophils
350 and lowering their degranulation threshold.

351 Tafazzin knockout neutrophils also show elevated rates of inflammatory NETotic cell
352 death in response to calcium mobilization, although this was not tested in circulating
353 BTHS patient neutrophils. Increased NET formation may lead to peripheral depletion
354 of neutrophils, possibly contributing to neutropenia. NET release is also a potent
355 inflammatory signal that activates macrophages and other immune cells [33, 34],
356 potentially lowering the threshold for acute and chronic inflammation [35, 36]. These
357 findings highlight a major knowledge gap on inflammatory processes in BTHS and
358 suggest that inflammation should be further investigated as an etiological factor in
359 BTHS.

360 Several mechanisms can be proposed for enhanced granule exocytosis and NETosis
361 in tafazzin deficient neutrophils. First, we observed elevated levels of intracellular
362 calcium in BTHS cultured and primary neutrophils; Ca^{2+} flux promotes neutrophil

363 degranulation [27, 29] and NET release [30]. Mitochondria are known to regulate
364 intracellular calcium stores [37] and this mechanism may be perturbed by alterations
365 in cardiolipin composition [10]. Secondly, it is known that ROS production, including
366 mtROS, can trigger the disassembly of filamentous actin (F-actin) [38-40], which is
367 needed for both mobilization of granules [41, 42] and NET formation [43]. We observed
368 elevated mtROS in BTHS neutrophils, suggesting that activation in BTHS may be
369 facilitated by ROS-induced actin degradation. Finally, degranulation is regulated by
370 UPR sensors, which we found to be dysregulated in both primary and cultured BTHS
371 neutrophils. In a model of acute lung injury, ER stress triggered by the IRE1/XBP1
372 pathway promotes degranulation, and specific depletion of XBP1 in neutrophils
373 reduces granule secretion [44]. Similarly, in lupus, neutrophils exhibit elevated IRE1 α
374 activity that was correlated with increased extracellular elastase activity [45]. These
375 findings imply that fluctuations in UPR during the physiological turnover of neutrophils
376 could influence their inflammatory response.

377 In contrast to previous findings associating tafazzin deficiency with disruptions in
378 mitochondrial respiration [46-49], we found no defects in the basal and maximal
379 respiratory rates nor in the rate of ATP production in circulating BTHS neutrophils,
380 although the interpretation of these findings is complicated by the fact that G-CSF-
381 mobilized immature neutrophils have elevated mitochondrial content and activity [24].
382 Neutrophils differ from other cells in that they have fewer mitochondria per cell, which
383 has traditionally led to the belief that these cells primarily rely on glycolysis and are not
384 dependent on active mitochondria; however, recent advancements have highlighted
385 the significance of these organelles in neutrophil development and function [50, 51].
386 Future studies should carefully examine mitochondrial metabolism in BTHS
387 progenitors.

388 Interestingly, our proteome analysis uncovered alternations in UPR and mtUPR
389 pathways in BTHS neutrophils, which is in accordance with findings from *Tafazzin*-KO
390 mice [23]. UPR pathways were traditionally linked with protein misfolding in the ER;
391 however, recently these signaling modules were recognized to play a crucial role in
392 regulation of immunity and inflammation [52]. For instance, experiments using HL-60
393 cells demonstrated that *in vitro* neutrophil differentiation relies on the stage-specific
394 expression of canonical UPR regulators. Notably, inhibition of these three proteins
395 reduced the expression of CD11b and morphological differentiation, which we also
396 confirmed in our primary cell culture system using PERK inhibitor GSK2606414.
397 Although the studies using *Tafazzin*-KO mice and HL-60 cells linked perturbations in
398 UPR with increased apoptosis [23, 53], as discussed above, we did not observe
399 differences in cell survival in cultured and circulating BTHS neutrophils. Neutropenia
400 is one of the symptoms of Wolcott-Rallison syndrome caused by mutations in the
401 *EIF2AK3* gene, which encodes PERK [54], and heightened ER stress was reported in
402 neutropenias caused by mutations in *ELANE* and glucose-6-phosphate subunit α gene
403 (*G6PC3*); [55-57]. These findings collectively highlight the importance of tightly
404 regulated UPR in neutrophil development.

405 In summary, we confirmed a partial block in neutrophil maturation in BTHS patients,
406 resulting in generation of fewer mature neutrophils from stem cells. Despite alterations
407 in phenotype and function, BTHS neutrophils maintain their anti-microbial activity and
408 display a hyperinflammatory phenotype. Potential causes of these changes could be
409 alterations in the UPR and calcium signaling pathways, which are currently recognized
410 as vital for neutrophil development and function. As neutropenia in BTHS patients has
411 irregular patterns, disruption of neutrophil differentiation may be triggered under non-
412 homeostatic conditions such as metabolic perturbations or other forms of cellular

413 stress. These conundrums imply the presence of underlying imbalances alongside
414 functional neutrophil precursors, necessitating further research to understand the
415 nuanced mechanisms at play.

416

417 **MATERIALS AND METHODS**

418 **Human subjects and samples**

419 The study was approved by NHS Research Ethics committee (permit number
420 09/H0202/52). Written informed consent was received from all patients and healthy
421 donors. The patient cohort consisted of 28 patients (27 male), while the controls
422 consisted of 31 individuals (27 male). Samples from some patients and healthy donors
423 were obtained multiple times. Patient genetic data (*TAFAZZIN* mutations) are listed in
424 Table 1. Venous blood was collected in EDTA tubes (BD Biosciences). For shRNA
425 and CRISPR/Cas9 experiments, HSC were isolated from apheresis blood (NHSBT,
426 Filton, Bristol, UK) with NHS REC approval (18/EE/0265).

427 **Mouse model and experiments**

428 All mouse experiments were performed in accordance with UK Home Office
429 regulations (Project License PP9886217), under the oversight of the Animal Welfare
430 and Ethical Review Board (AWERB) of the University of Glasgow.

431 The *Tafazzin* knockout mice were generated using G4 embryonic stem cells (isolated
432 from C57BL/6Ncr x 129S6/SvEvTac F1 mice). After germline transmission of the
433 targeted allele mice were bred for at least 10 generation to FVB/NCrl mice.

434 **CD34⁺ HSC isolation and neutrophil culture**

435 CD34⁺ HSCs were isolated either from peripheral blood of consented healthy donors
436 and BTHS patients or from apheresis blood and then cultured according to a modified
437 protocol of Naveh et al. [24]. In brief, peripheral blood mononuclear cells (PMBCs)
438 were isolated by density centrifugation using Histopaque®-1077 (Sigma-Aldrich)
439 according to manufacturer's instructions, followed by red cell lysis (55mM NH₄Cl,

440 0.137mM EDTA, 1mM KHCO₃, pH 7.5). CD34⁺ cells were enriched with a human
441 CD34 Microbead Kit (Miltenyi Biotec) according to manufacturer's protocol. For
442 peripheral blood HSCs, the cells were cultured in StemSpan™ Hematopoietic Cell
443 Media (STEMCELL™ Technologies) supplemented with 1% (v/v) penicillin-
444 streptomycin (P/S, Sigma-Aldrich) for the first 4 days and from day 5 of the culture,
445 cells were cultured in Iscove's Modified Dulbecco's Media (IMDM, Gibco™)
446 supplemented with 1% P/S and 10% (v/v) heat-inactivated fetal bovine serum (FBS,
447 Sigma-Aldrich). Cells isolated from apheresis blood were cultured in IMDM only.
448 Cytokines were added at the indicated concentrations and days of culture: stem cell
449 factor (SCF, 50 ng/mL; day 0-5 of culture), Flt-3 ligand (50 ng/mL; day 0-5 of culture),
450 interleukin-3 (IL-3, 10 ng/mL; day 0-5 of culture), granulocyte-macrophage colony-
451 stimulating factor (GM-CSF, 10 ng/mL; day 3-7 of culture), and granulocyte colony-
452 stimulating factor (G-CSF, 10 ng/mL; day 7-14 of culture). All inhibitors or activators
453 were added on day 3, 5, 7, 10 and 14 of the culture. All functional assays (unless
454 stated otherwise) were completed between Day 17 and 19 of culture.

455 **CRISPR-mediated knockout of *TAFAZZIN***

456 CRISPR/Cas9 genome editing was performed on day 3 cultured neutrophils, by
457 nucleofection of ribonuclear particles, as described in [24]. gRNAs were designed
458 using Knockout Guide Design (Synthego). The following sgRNAs were used
459 (Synthego, modified sgRNA with EZ scaffold):

460 TAZ+154413511: UGCAGACAUCUGCUUCACCA;

461 TAZ-154413490: GCAGAUGUCUGCAGCUGCAG;

462 scrambled control #1: GCACUACCAGAGCUAACUCA;

463 scrambled control #2: GUACGUCGGUAUAACUCCUC.

464 **shRNA-mediated knockdown of *TAFAZZIN***

465 shRNA knockdown was achieved using lentiviral transduction of day 3 cultured HSC.
466 HEK293T cells were transfected with psPAX2 and pMD2.G packaging vectors, along
467 with U6-based shRNA lentiviral vectors, with enhanced green fluorescent protein
468 (eGFP) as a marker (VectorBuilder Inc.). Virus was concentrated using Lenti-X™
469 Concentrator and added to the cultured neutrophils.

470 shRNA sequences:

471 shRNA 1: TGCTTCCTCAGTTACACAAAGCTCGAGCTTTGTGTAAGTGAAGCA

472 shRNA 2:

473 CTGTGGCATGTCGGAATGAATCTCGAGATTCATTCCGACATGCCACAG

474 shRNA 3: CGGACTTCATTCAAGAGGAATCTCGAGATTCCTCTTGAATGAAGTCCG

475 n-t shRNA (scrambled control):

476 CCTAAGGTTAAGTCGCCCTCGCTCGAGCGAGGGCGACTTAACCTTAGG

477 **Flow cytometry analysis**

478 The analysis was conducted as described in [25]. Briefly, cells were stained with 0.1%
479 Zombie™ live/dead stain (BioLegend) and incubated for 10 min in the dark at RT.
480 Samples were washed, incubated in Fc receptor blocking solution Human TruStain
481 FcX™ (BioLegend) diluted in MACS buffer (5 mM EDTA, 0.5% BSA in PBS) for 5 min,
482 and then a mix of primary antibodies in MACS was added followed by 30 min
483 incubation on ice. Samples then were washed twice with MACS buffer and fixed for
484 20 min with 2% formaldehyde in PBS. Cells were analyzed with BD LSRFortessa™
485 X-20 Cell Analyzer. OneComp eBeads™ (Invitrogen™) were used as a single-color
486 compensation control. For Annexin V positivity, cells were stained with FITC-Annexin

487 V (BioLegend). At least 10,000 events were recorded per sample, and then analyzed
488 in FlowJo™ software (version 9).

489 **Western blot**

490 Cells were lysed directly in 2x Bolt™ LDS sample buffer (Invitrogen™) supplemented
491 with Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific™) and
492 heated for 10 min at 70°C. Samples were sonicated and then run on 4-12% Bolt™ Bis-
493 Tris Plus Mini Protein gels (Invitrogen™), followed by transfer onto Immobilon®-FL
494 PVDF membrane (MERCCK), using a standard wet transfer protocol. The membrane
495 was blocked with 5% milk, incubated with primary antibodies overnight, and on the
496 following day with secondary antibodies for 1 h at RT. Blots were imaged using a LI-
497 COR Odyssey® XF Imager.

498 **PLB-985 cell culture and differentiation**

499 PLB-985 were cultured in RPMI-1640 (Sigma-Aldrich) supplemented with P/S and
500 10% FBS. After lentiviral transduction, cells were differentiated by replacing the media
501 with RPMI-1640 with P/S, 2.5% FBS, 0.5% DMF, 1x Nutridoma-CS (Roche) and
502 culturing for 7 days.

503 **Neutrophil isolation, oxidative burst, and NET formation**

504 Neutrophils were isolated using the EasySep™ Direct Human Neutrophil Isolation Kit
505 (STEMCELL™ Technologies) as per the manufacturer's instructions. ROS production
506 was quantified with the luminol method, as previously described [58].
507 Chemiluminescence was recorded in 2-minute intervals using a FLUOstar® Omega
508 plate reader (BMG LABTECH). NET assays were performed as described in [59]. Cells
509 were stimulated with 50nM PMA, 300nM fMLP, or 10µM A23187. NETs were stained

510 with SYTOX and SYTO dyes and imaged with either an EVOS® FL or Incucyte®
511 ZOOM imaging systems.

512 **MPO ELISA**

513 Plasma MPO was quantified using Human Myeloperoxidase DuoSet ELISA (R&D
514 Systems), according to manufacturer's instructions.

515 **Degranulation**

516 In experiments on circulating neutrophils, cells were stimulated with N-
517 formylmethionine-leucyl-phenylalanine (fMLP, 300nM) for 30 min or *Streptococcus*
518 *pyogenes* MGAS10270 for 40 min. For experiments on HSC-derived neutrophils, cells
519 were stimulated with A23187 (2.5µM) for 30 min. After stimulation, cells were stained
520 and fixed according to the flow cytometry protocol detailed above.

521 **Bacterial killing assay**

522 Neutrophils (2.5×10^6) were resuspended in 500µL HBSS and combined with 5×10^5
523 *Streptococcus pyogenes* MGAS10270 bacteria [60] in HBSS supplemented with 2mM
524 CaCl_2 , 2mM MgCl_2 and 10% pooled human serum (SEQUENS IVD). Samples were
525 incubated at 37°C with atmospheric CO_2 levels on a rotator. Aliquots (50µL) of each
526 sample were taken immediately and thereafter every hour for 4 hours, and numbers
527 of viable bacteria enumerated following plating onto Todd-Hewitt agar plates
528 supplemented with 0.5% (w/v) yeast extract and incubation overnight at 37°C, 5%
529 CO_2 . Killing efficiency was calculated as number of colonies with neutrophils/number
530 of colonies with serum only.

531 **Fluorescent immunohistochemistry and mouse whole blood analysis**

532 Lung and spleen sections of germline *Tafazzin* *-/-* mice, were stained for neutrophil
533 abundance with a neutrophil-specific calgranulin antibody, as previously described
534 [61]. Tissue sections were imaged with a Leica DMI6000 inverted epifluorescence
535 microscope and analysis was performed with ImageJ Fiji. For whole blood analysis,
536 mice were tail vein bled, and blood sample analysis was performed using the Procyte
537 DX Hematology analyzer.

538 **Phagocytosis**

539 Heat-killed *Streptococcus pyogenes* MGAS10270 (1×10^9) were stained with pHrodo™
540 Phagocytosis Particle Labeling Kit for Flow Cytometry (Invitrogen™) following the
541 manufacturer's protocol. Neutrophils (2×10^6) were resuspended in 500 μ L RPMI+Q
542 and 2×10^8 pHrodo-stained *Streptococcus pyogenes* were added for an MOI = 100.
543 Suspensions were incubated with rotation at 37°C for 1 h, taking 100 μ l aliquots at
544 multiple time points. Cells were then washed once and analyzed using BD
545 LSRFortessa™ X-20 Cell Analyzer.

546 **Seahorse metabolic flux analysis**

547 Seahorse assay was performed according to the protocol in [24] using Seahorse
548 XFe96 microplates (Agilent) and Seahorse XF DMEM medium (Agilent).

549 **Mitochondrial labelling**

550 To label mitochondria, cells were incubated with 25 nM tetramethylrhodamine, ethyl
551 ester, perchlorate (TMRE, Invitrogen™), 5 μ M MitoSox™ Red (Invitrogen™), or 5 nM
552 MitoTracker™ green (Invitrogen™) in prewarmed HBSS. Cells were incubated with
553 each dye for 20 min at 37°C, washed with fresh media, resuspended in MACS buffer,
554 and analyzed using BD LSRFortessa™ X-20 Cell Analyzer.

555 **Intracellular calcium**

556 Levels of intracellular Ca²⁺ were determined using the cell permeant calcium indicator
557 X-Rhod-1, AM (Invitrogen™). Cells were incubated with 500 nM X-Rhod-1 in RPMI for
558 1 h at 37°C, thoroughly washed with fresh media, resuspended in MACS buffer, and
559 analyzed with BD LSRFortessa™ X-20 Cell Analyzer.

560 **Proteomics and bioinformatics analysis**

561 Isolated peripheral blood neutrophils from patients and controls were lysed and
562 labeled with tandem mass spectrometry reagents (Thermo Fisher), as previously
563 described [25]. Peptides were identified by nano LC-MS/MS with a Orbitrap™ Fusion
564 Tribrid™ Mass Spectrometer (Thermo Scientific™). Raw files were analyzed using
565 Proteome Discoverer™ software v. 2 and cross-referenced against the human UniProt
566 database (human). The protein groups were reassessed by an in-house script which
567 initially selects a master protein by ID and quantitation metrics, then by annotation
568 quality of Uniprot accessions. Data were log₂ transformed and tested for statistical
569 significance using Welch's *t* test. IPA analysis was performed with a filter of $P < 0.05$
570 to identify biological trends in the proteins that were statistically significant between
571 conditions. PCAs were calculated using the PCA function in the FactoMineR package
572 and plotted using either ggplot (2D) or Plotly (3D).

573 **Statistical analysis**

574 The analysis was performed using GraphPad Prism 8 software. All the data are
575 presented as mean ± SD. Unless stated otherwise, all “n” numbers represent the
576 number of blood samples. Statistical analysis was completed, where appropriate,
577 using *t* test when comparing two different samples, or one-way/two-way ANOVA
578 where multiple samples were being examined.

579 **FIGURE LEGENDS**

580 **Fig. 1. Tafazzin regulates neutrophil development**

581 **A.** Wright-Giemsa staining of 8 bone marrow aspirates from BTHS patients. The
582 normal range (grey) represents values for healthy children. Samples from the same
583 patient, obtained at different ages, are marked in red. **B.** Myeloid:erythroid ratio for
584 samples analysed in A. **C.** Simplified overview of culture protocol for deriving
585 neutrophils from HSC. **D.** Growth curve of *ex vivo* HSC-derived neutrophil, n = 9 (HC),
586 8 (BTHS). **E.** Fold change of total cell count of HSC-derived neutrophils from day 3 to
587 day 17 of differentiation, n = 9 (HC), 8 (BTHS); ns – not significant. **F.** Percent of
588 CD66b⁺CD15⁺ neutrophils in HSC-derived cells at the end of differentiation, n = 9
589 (HC), 8 (BTHS); * P ≤ 0.05. **G.** CD11b surface expression of CD66b⁺CD15⁺ HSC-
590 derived neutrophils at the end of differentiation, relative to averaged CD11b
591 expression of control cells on a same day, n = 9 (HC), 8 (BTHS); * P ≤ 0.05. **H.** CD11b
592 surface expression of control or tafazzin shRNA-treated CD66b⁺CD15⁺GFP⁺ HSC-
593 derived neutrophils at the end of differentiation, relative to n-t shRNA control, n = 9
594 (HC), 8 (BTHS); * P ≤ 0.05. **I.** Representative tafazzin Western blot of CRISPR/Cas9-
595 edited HSC-derived neutrophils at the end of differentiation. **J.** Growth curve of
596 CRISPR/Cas9-edited HSC-derived neutrophils, n = 3 (experimental repeats). **K.**
597 CD11b surface expression of CD66b⁺CD15⁺ CRISPR/Cas9-edited HSC-derived
598 neutrophils at the end of differentiation, relative to scrambled gRNA control, n = 4; * P
599 ≤ 0.05.

600

601

602 **Fig. S1. Impaired terminal differentiation and maturation of BTHS neutrophils ex**
603 ***vivo*.**

604 **A.** Representative image of BTHS patient bone marrow aspirate. **B.** Quantification of
605 average percentage of apoptotic (AV+PI-) and necrotic (AV+PI+) HSC-derived
606 neutrophils at the end of differentiation, n = 2 (HC), 3 (BTHS); ns – not significant. **C.**
607 Representative cytopspins of HSC-derived neutrophils (day 17). **D.** Gating strategy for
608 HSC-derived neutrophils (day 17). **E.** Average percentage of CD66b⁺CD15⁺CD11^{hi}
609 cells in live population of HSC-derived neutrophils at day 17, n = 9 (HC), 8 (BTHS) **F.**
610 Representative Western blot depicting level of tafazzin expression and graph showing
611 CD11b surface expression of PLB-985 cells transduced with lentivirus encoding non-
612 targeting (n-t) or anti-*TAFAZZIN* shRNAs, n = 2 (experimental repeats). **G.**
613 Representative Western blot and graph depicting level of tafazzin expression level of
614 GFP⁺ HSC-derived neutrophils transduced with lentivirus encoding non-targeting (n-t)
615 or anti-*TAFAZZIN* shRNAs, n = 3 (experimental repeats), * P ≤ 0.05. **H.** Fold change
616 of total cell count of CRISPR/Cas9-edited HSC-derived neutrophils from day 3 to day
617 17 of differentiation matching tafazzin knockout cells to their relative controls, n = 4; *
618 P ≤ 0.05.

619

620 **Fig. 2. Characterization of peripheral blood neutrophils from BTHS patients.**

621 **A.** Surface expression of CD10 (left) and CD16 (right) in circulating neutrophils, n =
622 15 (HC, BTHS); * $P \leq 0.05$. **B.** Surface expression of CD66b in circulating neutrophils,
623 n = 12 (HC), 15 (BTHS); *** $P \leq 0.001$. **C.** Surface expression of CD63 in unstimulated
624 (unstim) and fMLP-stimulated (300 nM) isolated neutrophils, n (unstim) = 29 (HC,
625 BTHS), n (fMLP) = 31 (HC, BTHS); ns – not significant, ** $P \leq 0.01$. **D.** Time-course of
626 CD66b surface expression in isolated neutrophils stimulated with *Streptococcus*
627 *pyogenes*, MOI = 100, n = 9 (HC), 7 (BTHS). **E.** MPO concentration in plasma, n = 20
628 (HC), 19 (BTHS); * $P \leq 0.05$. **F.** Percentage of annexin V+ unstimulated neutrophils, n
629 = 6 (HC, BTHS); * $P \leq 0.05$ **G.** Percentage of annexin V+ neutrophils, after stimulation
630 with 300 nM fMLP, n = 6 (HC, BTHS); ns – not significant. **H.** Area under the curve
631 (AUC) quantification of ROS, detected by luminol, n (unstim, PMA) = 10 (HC), 12
632 (BTHS), n (ConA) = 8 (HC), 10 (BTHS); ns – not significant. **I.** NET release in response
633 to 50 nM PMA, n = 7 (HC), 8 (BTHS); ns – not significant. **J.** Quantification of viable
634 *Streptococcus pyogenes* bacteria relative to “serum only” control, after incubation with
635 isolated neutrophils, n = 4 (HC, BTHS).

636 **Fig. S2. Additional analyses of peripheral blood neutrophils**

637 **A.** Surface expression of CD10 (left) and CD16 (right) in circulating neutrophils
638 stratified according to G-CSF therapy; n = 15 (HC), 11 (BTHS+G-CSF), 4 (BTHS-G-
639 CSF); * $P \leq 0.05$, ns – not significant. **B.** Surface expression of CD62L (left) and CD101
640 (right) in circulating neutrophils, n = 15 (HC, BTHS); ns – not significant. **C.** Surface
641 expression of CD66b in neutrophils stratified according to G-CSF treatment, n = 12
642 (HC), 10 (BTHS+G-CSF), 5 (BTHS-G-CSF); * $P \leq 0.05$, **** $P \leq 0.0001$. **D.**
643 Representative epifluorescence images showing anti-calgranulin (green) and DAPI

644 (blue) staining of mouse lung and spleen (left) and quantification of average number
645 of calgranulin-positive cells per mm² of section (right), n = 2 (mouse per genotype; the
646 cells were counted from one transverse section through the middle part of the tissue).

647 **E.** Percentage of neutrophils in mouse whole blood, n = 7 (WT), 8 (KO), ns – not
648 significant. **F.** Phagocytosis time-course, measured by pHrodo fluorescence in
649 isolated neutrophils, n = 3 (HC, BTHS).

650

651 **Fig. 3. Mitochondrial perturbations in BTHS patient circulating neutrophils.**

652 **A.** Average MitoTracker median fluorescence of isolated BTHS patient circulating
653 neutrophils normalized to HC (on the same day), n = 11 (HC, BTHS); *** $P \leq 0.001$. **B.**
654 Average percentage of neutrophils with low TMRE signal, n = 18 (HC), 17 (BTHS); *
655 $P \leq 0.05$. **C.** Average rates of ATP production, basal respiration, maximal respiration,
656 and spare respiratory capacity, measured by Seahorse metabolic flux analyzer, n
657 (ATP) = 6 (HC), 11 (BTHS), n (basal, maximal, spare respiration) = 6 (HC), 8 (BTHS);
658 ns – not significant. **D.** Percentage of MitoSOX-positive neutrophils n = 13 (HC, BTHS).
659 **E.** Percentage of MitoSOX-positive neutrophils, after stimulation with 300 nM fMLP, n
660 = 8 (HC), 9 (BTHS); ** $P \leq 0.01$.

661 **Fig. S3. Additional mitochondrial analyses in BTHS neutrophils.**

662 **A.** Quantification of average mitoSOX median fluorescence of circulating neutrophils,
663 n = 13 (HC, BTHS); ns – not significant. **B.** Quantification of average mitoSOX median
664 fluorescence of circulating neutrophils stimulated with 300 nM fMLP, n = 8 (HC), 9
665 (BTHS), ns – not significant. **C.** Percentage of mitoSOX-positive HSC-derived
666 neutrophils at the end of differentiation (D17), n = 3 (HC, BTHS); ns – not significant.
667 **D.** Percentage of mitoSOX-positive HSC-derived neutrophils (D17), after stimulation
668 with 300 nM fMLP, n = 3 (HC, BTHS); ns – not significant.

669

670 **Fig. 4. Calcium homeostasis in BTHS neutrophils.**

671 **A.** Average median fluorescence of calcium dye X-Rhod-1, normalized to HC (on the
672 same day), n = 11 (HC), 8 (BTHS); ** P ≤ 0.01. **B.** Quantification of average median
673 fluorescence of X-Rhod-1 in HSC-derived BTHS neutrophils (D17), n = 3 (HC, BTHS);
674 * P ≤ 0.05. **C.** An example of histogram depicting CD63 surface expression in HSC-
675 derived neutrophils before and after stimulation with A23187 and surface expression
676 of CD63 in unstimulated (unstim) and A23187-stimulated (2.5 μM) CRISPR/Cas9-
677 edited HSC-derived neutrophils, n (unstim) = 4, n (A23) = 4; ns – not significant. **D.**
678 Quantification of NET release by CRISPR/Cas9-edited HSC-derived neutrophils
679 before or after stimulation with PMA (50nM) at 4 h post-stimulation, n = 4; ns – not
680 significant. **E.** Calculation of NET release by CRISPR/Cas9-edited HSC-derived
681 neutrophils before or after stimulation with A23187 (10 μM) at 4 h post-stimulation, n
682 = 4; ns – no significant, * P ≤ 0.05.

683

684 **Fig. 5. Elevated UPR signaling in BTHS neutrophils.**

685 **A.** Plot showing significantly upregulated (positive Z-score, red) and downregulated
686 (negative Z-score, blue) IPA canonical pathways in circulating neutrophils from BTHS
687 patients. **B.** Heat map depicting upregulated UPR-related proteins in circulating BTHS
688 neutrophils, displayed as log₂ fold change over HC, * P ≤ 0.05, ** P ≤ 0.01. **C.** Heat
689 map depicting upregulated mitochondrial UPR-related proteins in circulating BTHS
690 neutrophils, displayed as log₂ fold change over HC, * P ≤ 0.05, ** P ≤ 0.01, *** P ≤
691 0.001, **** P ≤ 0.0001; B-C: *BTHS5* - non-neutropenic BTHS patient. **D.** Western blot
692 of selected UPR-related proteins in HC or BTHS patient HSC-derived neutrophils at
693 the end of differentiation (D17), n = 3 (HC, BTHS); asterisks indicate nonspecific
694 bands. **E.** Average percentage of HSC-derived neutrophils (CD66b⁺CD15⁺) and
695 mature neutrophils (CD66b⁺CD15⁺CD11b^{hi}) at D17, after treatment with PERK
696 inhibitor (GSK2606414; 1 μM, added on day 3, 5, 7, 10, and 14 of culture) or vehicle
697 control (DMSO), n = 9 (DMSO, PERKi); * P ≤ 0.05. **F.** Average percentage of HSC-
698 derived neutrophils (CD66b⁺CD15⁺) and mature neutrophils (CD66b⁺CD15⁺CD11b^{hi})
699 at D17, after treatment with PERK activator (CCT020312; 1 μM, added on day 3, 7,
700 10, and 14 of culture) or vehicle control (DMSO), n = 4 (DMSO, PERKa); ns – not
701 significant.

702 **Fig. S5. Elevated UPR signaling in BTHS neutrophils.**

703 **A.** Volcano plot comparing BTHS and HC circulating neutrophil protein abundances,
704 displayed as -log₁₀ P-value and log₂ fold change. **B.** Heat map depicting upregulated
705 oxidative phosphorylation proteins identified with IPA, displayed as log₂ fold change
706 over HC, * P ≤ 0.05, ** P ≤ 0.01. **C.** Heat map depicting upregulated fatty acid oxidation
707 proteins identified with IPA, displayed as log₂ fold change over HC, * P ≤ 0.05, ** P ≤

708 0.01; B-C: *BTHS5* - non-neutropenic BTHS patient. **D.** Log₂ normalized abundance of
709 mtUPR-related proteins identified by proteomics in circulating neutrophils, * P ≤ 0.05,
710 ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001. **E.** Quantification of UPR-related protein
711 expression in HSC-derived neutrophils at D17 of differentiation, n = 3 (HC, BTHS); ns
712 – not significant, * P ≤ 0.05. **F.** Surface expression of CD11b in PERK-inhibited cells
713 (GSK2606414; 1 μM) or vehicle control (DMSO-treated) HSC-derived neutrophils at
714 D17 of differentiation, relative to averaged control (on a same day), n = 9 (DMSO,
715 PERKi); ns – not significant. **G.** Fold change in total cell count during HSC
716 differentiation, from day 3 to day 17, after treatment with PERK inhibitor
717 (GSK2606414; 1 μM) or vehicle control (DMSO), relative to averaged CD11b
718 expression of vehicle control cells on a same day, n = 9 (DMSO, PERKi); ** P ≤ 0.01.
719 **H.** Surface expression of CD11b in PERK-activated cells (CCT020312; 1 μM) or
720 vehicle control (DMSO-treated) HSC-derived neutrophils at D17 of differentiation,
721 relative to averaged control (on a same day), n = 4 (DMSO, PERKa); ns – not
722 significant. **I.** Fold change in total cell count during HSC differentiation, from day 3 to
723 day 17, after treatment with PERK activator (CCT020312; 1 μM) or vehicle control
724 (DMSO), relative to averaged CD11b expression of vehicle control cells on a same
725 day, n = 4 (DMSO, PERKa); ns – no significant.

726

727 **DECLARATIONS**

728 **Ethics approval and consent to participate**

729 Patient blood samples were collected with approval from National Health Service
730 Research Ethics Committee (REC), 09/H0202/52. Apheresis and healthy control blood
731 samples were collected under NHS REC 18/EE/0265.

732 **Availability of data and materials**

733 The research materials supporting this publication can be accessed by
734 contacting corresponding authors.

735 The mass spectrometry proteomics data have been deposited to the
736 ProteomeXchange Consortium via the PRIDE [62] partner repository with the dataset
737 identifier PXD052714.

738 **Competing interests**

739 The authors declare that they have no competing interests.

740 **Author contributions**

741 **PZ, CR, DC, SG, FP, WG, KR, TP, EA** and **BA** performed experiments and analyzed
742 data; **KF** organized access to and analysis of bone marrow aspirates; **DS** provided
743 mouse samples; **AHN** supervised bacterial experiments; **BA, CS** and **AT** conceived
744 and supervised the study and acquired funding. **PZ** and **BA** wrote the manuscript.

745 All authors read, provided input, and approved the final manuscript.

746 **Funding**

747 This work was funded by Barth Syndrome Foundation (Idea Grants to BA and CS), by
748 Bristol & Weston Hospitals Charity (through funds provided by the COGENT Trust),

749 as well as MRC grant MR/R02149X/1 to BA. KF was funded by GW4-CAT Wellcome
750 Trust Clinical PhD Fellowship. AT was funded by an NHS Blood and Transplant
751 (NHSBT) R&D grant (WP15-05) and a National Institute for Health Research Blood
752 and Transplant Research Unit (NIHR BTRU) in Red Blood Cell Products at the
753 University of Bristol in partnership with NHSBT (IS-BTU-1214-10032). KTR was
754 funded by a Wellcome Trust Dynamic Cell PhD studentship. DS was funded by CRUK
755 Scotland Institute core funding (A31287). The views expressed are those of the
756 authors and not necessarily of the NHS, the NIHR or the Department of Health.

757 **ACKNOWLEDGMENTS**

758 We thank all the patients and blood donors for participating in our study, as well as
759 nurses and clinical staff at the NHS Barth Syndrome Service and Bristol Children's
760 Hospital. We acknowledge the assistance and support from Gillian Alexander, Maria
761 Pelidis, Effie Chronopoulou, Rachel Schwartz, Olivia Gordon, Sally Turner, and
762 Germaine Pierre. We also thank Jane Brittan for technical assistance with the bacterial
763 experiments.

764


765 **REFERENCES**

- 766 1. Clarke, S.L., et al., *Barth syndrome*. Orphanet J Rare Dis, 2013. **8**: p. 23.
- 767 2. Saric, A., et al., *Barth Syndrome: From Mitochondrial Dysfunctions Associated with*
768 *Aberrant Production of Reactive Oxygen Species to Pluripotent Stem Cell Studies*. Front
769 Genet, 2015. **6**: p. 359.
- 770 3. Taylor, C., et al., *Clinical presentation and natural history of Barth Syndrome: An*
771 *overview*. J Inherit Metab Dis, 2022. **45**(1): p. 7-16.
- 772 4. Bione, S., et al., *A novel X-linked gene, G4.5. is responsible for Barth syndrome*. Nat
773 Genet, 1996. **12**(4): p. 385-9.
- 774 5. Paradies, G., et al., *Role of Cardiolipin in Mitochondrial Function and Dynamics in Health*
775 *and Disease: Molecular and Pharmacological Aspects*. Cells, 2019. **8**(7).
- 776 6. Greenwell, A.A., S.A. Tabatabaei Dakhili, and J.R. Ussher, *Myocardial disturbances of*
777 *intermediary metabolism in Barth syndrome*. Front Cardiovasc Med, 2022. **9**: p. 981972.
- 778 7. Patil, V.A. and M.L. Greenberg, *Cardiolipin-mediated cellular signaling*. Adv Exp Med Biol,
779 2013. **991**: p. 195-213.
- 780 8. Pizzuto, M. and P. Pelegrin, *Cardiolipin in Immune Signaling and Cell Death*. Trends Cell
781 Biol, 2020. **30**(11): p. 892-903.
- 782 9. Dudek, J., *Role of Cardiolipin in Mitochondrial Signaling Pathways*. Front Cell Dev Biol,
783 2017. **5**: p. 90.
- 784 10. Ghosh, S., et al., *An essential role for cardiolipin in the stability and function of the*
785 *mitochondrial calcium uniporter*. Proc Natl Acad Sci U S A, 2020. **117**(28): p. 16383-
786 16390.
- 787 11. Wilson, L.D., et al., *Higher IL-6 and IL6:IGF Ratio in Patients with Barth Syndrome*. J
788 Inflamm (Lond), 2012. **9**(1): p. 25.
- 789 12. Steward, C.G., et al., *Neutropenia in Barth syndrome: characteristics, risks, and*
790 *management*. Curr Opin Hematol, 2019. **26**(1): p. 6-15.
- 791 13. Mayadas, T.N., X. Cullere, and C.A. Lowell, *The multifaceted functions of neutrophils*.
792 Annu Rev Pathol, 2014. **9**: p. 181-218.
- 793 14. Amulic, B., et al., *Neutrophil function: from mechanisms to disease*. Annu Rev Immunol,
794 2012. **30**: p. 459-89.
- 795 15. Rankin, S.M., *The bone marrow: a site of neutrophil clearance*. J Leukoc Biol, 2010. **88**(2):
796 p. 241-51.
- 797 16. Papadaki, H.A. and G.D. Eliopoulos, *Enhanced neutrophil extravasation may be a*
798 *contributing factor in the determination of neutropenia in patients with chronic idiopathic*
799 *neutropenia of adults*. Eur J Haematol, 1998. **61**(4): p. 272-7.
- 800 17. Duchene, J., et al., *Atypical chemokine receptor 1 on nucleated erythroid cells regulates*
801 *hematopoiesis*. Nat Immunol, 2017. **18**(7): p. 753-761.
- 802 18. Barth, P.G., et al., *An X-linked mitochondrial disease affecting cardiac muscle, skeletal*
803 *muscle and neutrophil leucocytes*. J Neurol Sci, 1983. **62**(1-3): p. 327-55.
- 804 19. Kuijpers, T.W., et al., *Neutrophils in Barth syndrome (BTHS) avidly bind annexin-V in the*
805 *absence of apoptosis*. Blood, 2004. **103**(10): p. 3915-23.
- 806 20. Makaryan, V., et al., *The cellular and molecular mechanisms for neutropenia in Barth*
807 *syndrome*. Eur J Haematol, 2012. **88**(3): p. 195-209.
- 808 21. Wang, S., et al., *AAV Gene Therapy Prevents and Reverses Heart Failure in a Murine*
809 *Knockout Model of Barth Syndrome*. Circ Res, 2020. **126**(8): p. 1024-1039.
- 810 22. Phoon, C.K., et al., *Tafazzin knockdown in mice leads to a developmental*
811 *cardiomyopathy with early diastolic dysfunction preceding myocardial noncompaction*. J
812 Am Heart Assoc, 2012. **1**(2).


- 813 23. Sohn, J., et al., *A new murine model of Barth syndrome neutropenia links TFAZZIN*
814 *deficiency to increased ER stress-induced apoptosis*. *Blood Adv*, 2022. **6**(8): p. 2557-
815 2577.
- 816 24. Naveh, C.A., et al., *Neutrophils cultured ex vivo from CD34⁺ stem cells are immature and*
817 *genetically tractable*. 2024. **22**(1): p. 526.
- 818 25. Rice, C.M., et al., *Hyperactive immature state and differential CXCR2 expression of*
819 *neutrophils in severe COVID-19*. *Life Sci Alliance*, 2023. **6**(2).
- 820 26. Marini, O., et al., *Mature CD10(+) and immature CD10(-) neutrophils present in G-CSF-*
821 *treated donors display opposite effects on T cells*. *Blood*, 2017. **129**(10): p. 1343-1356.
- 822 27. Liu, X., et al., *Increased Reactive Oxygen Species-Mediated Ca(2+)/Calmodulin-*
823 *Dependent Protein Kinase II Activation Contributes to Calcium Handling Abnormalities*
824 *and Impaired Contraction in Barth Syndrome*. *Circulation*, 2021. **143**(19): p. 1894-1911.
- 825 28. Feno, S., et al., *Crosstalk between Calcium and ROS in Pathophysiological Conditions*.
826 *Oxid Med Cell Longev*, 2019. **2019**: p. 9324018.
- 827 29. Hann, J., et al., *Calcium signaling and regulation of neutrophil functions: Still a long way*
828 *to go*. *J Leukoc Biol*, 2020. **107**(2): p. 285-297.
- 829 30. Kenny, E.F., et al., *Diverse stimuli engage different neutrophil extracellular trap pathways*.
830 *Elife*, 2017. **6**.
- 831 31. Frasch, S.C., et al., *NADPH oxidase-dependent generation of lysophosphatidylserine*
832 *enhances clearance of activated and dying neutrophils via G2A*. *J Biol Chem*, 2008.
833 **283**(48): p. 33736-49.
- 834 32. Frasch, S.C., et al., *Phospholipid flip-flop and phospholipid scramblase 1 (PLSCR1) co-*
835 *localize to uropod rafts in formylated Met-Leu-Phe-stimulated neutrophils*. *J Biol Chem*,
836 2004. **279**(17): p. 17625-33.
- 837 33. Apel, F., et al., *The cytosolic DNA sensor cGAS recognizes neutrophil extracellular traps*.
838 *Sci Signal*, 2021. **14**(673).
- 839 34. Knackstedt, S.L., et al., *Neutrophil extracellular traps drive inflammatory pathogenesis in*
840 *malaria*. *Sci Immunol*, 2019. **4**(40).
- 841 35. Wigerblad, G. and M.J. Kaplan, *Neutrophil extracellular traps in systemic autoimmune*
842 *and autoinflammatory diseases*. *Nat Rev Immunol*, 2023. **23**(5): p. 274-288.
- 843 36. Castanheira, F.V.S. and P. Kubes, *Neutrophils and NETs in modulating acute and chronic*
844 *inflammation*. *Blood*, 2019. **133**(20): p. 2178-2185.
- 845 37. Romero-Garcia, S. and H. Prado-Garcia, *Mitochondrial calcium: Transport and*
846 *modulation of cellular processes in homeostasis and cancer (Review)*. *Int J Oncol*, 2019.
847 **54**(4): p. 1155-1167.
- 848 38. Sakai, J., et al., *Reactive oxygen species-induced actin glutathionylation controls actin*
849 *dynamics in neutrophils*. *Immunity*, 2012. **37**(6): p. 1037-49.
- 850 39. Vorobjeva, N., et al., *Mitochondrial reactive oxygen species are involved in*
851 *chemoattractant-induced oxidative burst and degranulation of human neutrophils in*
852 *vitro*. *Eur J Cell Biol*, 2017. **96**(3): p. 254-265.
- 853 40. Yadav, T., D. Gau, and P. Roy, *Mitochondria-actin cytoskeleton crosstalk in cell migration*.
854 *J Cell Physiol*, 2022. **237**(5): p. 2387-2403.
- 855 41. Jog, N.R., et al., *The actin cytoskeleton regulates exocytosis of all neutrophil granule*
856 *subsets*. *Am J Physiol Cell Physiol*, 2007. **292**(5): p. C1690-700.
- 857 42. Mitchell, T., et al., *Primary granule exocytosis in human neutrophils is regulated by Rac-*
858 *dependent actin remodeling*. *Am J Physiol Cell Physiol*, 2008. **295**(5): p. C1354-65.
- 859 43. Metzler, K.D., et al., *A myeloperoxidase-containing complex regulates neutrophil*
860 *elastase release and actin dynamics during NETosis*. *Cell Rep*, 2014. **8**(3): p. 883-96.
- 861 44. Hu, R., et al., *Endoplasmic Reticulum Stress of Neutrophils Is Required for*
862 *Ischemia/Reperfusion-Induced Acute Lung Injury*. *J Immunol*, 2015. **195**(10): p. 4802-9.

- 863 45. Sule, G., et al., *Endoplasmic reticulum stress sensor IRE1alpha propels neutrophil*
864 *hyperactivity in lupus*. J Clin Invest, 2021. **131**(7).
- 865 46. Lou, W., et al., *Loss of tafazzin results in decreased myoblast differentiation in C2C12*
866 *cells: A myoblast model of Barth syndrome and cardiolipin deficiency*. Biochim Biophys
867 Acta Mol Cell Biol Lipids, 2018. **1863**(8): p. 857-865.
- 868 47. Dudek, J., et al., *Cardiolipin deficiency affects respiratory chain function and organization*
869 *in an induced pluripotent stem cell model of Barth syndrome*. Stem Cell Res, 2013. **11**(2):
870 p. 806-19.
- 871 48. Hsu, P., et al., *Cardiolipin remodeling by TAZ/tafazzin is selectively required for the*
872 *initiation of mitophagy*. Autophagy, 2015. **11**(4): p. 643-52.
- 873 49. Kagan, V.E., et al., *Anomalous peroxidase activity of cytochrome c is the primary*
874 *pathogenic target in Barth syndrome*. Nat Metab, 2023. **5**(12): p. 2184-2205.
- 875 50. Cao, Z., et al., *Roles of mitochondria in neutrophils*. Front Immunol, 2022. **13**: p. 934444.
- 876 51. Vorobjeva, N.V., et al., *Role of Mitochondria in the Regulation of Effector Functions of*
877 *Granulocytes*. Cells, 2023. **12**(18).
- 878 52. Grootjans, J., et al., *The unfolded protein response in immunity and inflammation*. Nat
879 Rev Immunol, 2016. **16**(8): p. 469-84.
- 880 53. Tanimura, A., et al., *Mitochondrial Activity and Unfolded Protein Response are Required*
881 *for Neutrophil Differentiation*. Cell Physiol Biochem, 2018. **47**(5): p. 1936-1950.
- 882 54. Lundgren, M., et al., *Practical management in Wolcott-Rallison syndrome with*
883 *associated hypothyroidism, neutropenia, and recurrent liver failure: A case report*. Clin
884 Case Rep, 2019. **7**(6): p. 1133-1138.
- 885 55. Nanua, S., et al., *Activation of the unfolded protein response is associated with impaired*
886 *granulopoiesis in transgenic mice expressing mutant Elane*. Blood, 2011. **117**(13): p.
887 3539-47.
- 888 56. Sapa, A., et al., *Effect of the unfolded protein response and oxidative stress on*
889 *mutagenesis in CSF3R: a model for evolution of severe congenital neutropenia to*
890 *myelodysplastic syndrome/acute myeloid leukemia*. Mutagenesis, 2020. **35**(5): p. 381-
891 389.
- 892 57. Boztug, K., et al., *A syndrome with congenital neutropenia and mutations in G6PC3*. N
893 Engl J Med, 2009. **360**(1): p. 32-43.
- 894 58. Harbort, C.J., et al., *Neutrophil oxidative burst activates ATM to regulate cytokine*
895 *production and apoptosis*. Blood., 2015. **126**(26): p. 2842-51. doi: 10.1182/blood-2015-
896 05-645424. Epub 2015 Oct 21.
- 897 59. Amulic, B., et al., *Cell-Cycle Proteins Control Production of Neutrophil Extracellular*
898 *Traps*. Dev Cell, 2017. **43**(4): p. 449-462.e5.
- 899 60. Beres, S.B. and J.M. Musser, *Contribution of exogenous genetic elements to the group A*
900 *Streptococcus metagenome*. PLoS One, 2007. **2**(8): p. e800.
- 901 61. Cela, D., et al., *PAD4 controls chemoattractant production and neutrophil trafficking in*
902 *malaria*. J Leukoc Biol, 2022. **111**(6): p. 1235-1242.
- 903 62. Perez-Riverol, Y., et al., *The PRIDE database resources in 2022: a hub for mass*
904 *spectrometry-based proteomics evidences*. Nucleic Acids Res, 2022. **50**(D1): p. D543-
905 D552.


906




A




B




C




D




E





F




PLB-985





G




H









A




B fMLP stimulated








C












D









Genetic information of patients

| mutation | effect | exon/intron |
|-----------------------|--|-------------|
| c.9_10dupG | p.His4Alafs*130; frameshift | exon 1 |
| c.51G>A | p.Trp17*; nonsense | exon 1 |
| c.82_84delGTG | p.Val28del; deletion | exon 1 |
| c.118A>G ¹ | p.Asn40Asp; missense | exon 2 |
| c.149T>C | p.Leu50Pro; missense | exon 2 |
| c.182del | deletion/frameshift | exon 2 |
| c.207C>G | p.His69Gln; missense | exon 2 |
| c.216C>A | p.Cys72*; nonsense | exon 2 |
| c.228_232del | deletion/frameshift | exon 2 |
| c.239G>A | p.Gly80Glu or RNA splicing; missense | exon 3 |
| c.281G>A ¹ | p.Arg94His; missense | exon 3 |
| c.346G>C | p.Gly116Arg; missense | exon 3 |
| c.547_548insdel | insertion-deletion | exon 7 |
| c.553A>G | new exonic splicing donor at codon Met185; p.Lys182Glnfs*4; frameshift | exon 7 |
| c.581G>A | p.Trp194*; nonsense | exon 7 |
| c.583+5G>A | GTAAGG>GTAAAG; RNA splicing | intron 7 |
| c.589G>A ² | p.Gly197Arg; missense | exon 8 |
| c.589G>T | p.Gly197Trp; missense | exon 8 |
| c.646+1del | deletion/frameshift | exon 8 |
| c.809_812del | deletion/frameshift | exon 11 |
| c.837_838delTC | p.Gln280Glyfs*30; frameshift | exon 11 |

¹Variant present in 2 patients

² Variant present in 4 patients

For 1 patient variant was unknown.

For more details on *TAFAZZIN* variants please refer to Human *TAFAZZIN* Gene Variant Database at: <https://www.barthysyndrome.org/research/tafazzindatabase.html>